Standard Biotools Inc traded at $1.26 this Friday February 6th, increasing $0.02 or 1.61 percent since the previous trading session. Looking back, over the last four weeks, Standard Biotools gained 1.56 percent. Over the last 12 months, its price fell by 8.70 percent. Looking ahead, we forecast Standard Biotools Inc to be priced at 1.36 by the end of this quarter and at 1.24 in one year, according to Trading Economics global macro models projections and analysts expectations.
Fluidigm Corporation creates, manufactures, and markets a range of products and services, including instruments, consumables, reagents, and software that are used by researchers and clinical labs. The Company operates in development, manufacturing, and commercialization of tools for life sciences research. Its technology, mass cytometry is a multiplexed solution to analyze cell-surface and intracellular proteins simultaneously in cell suspensions including blood and disassociated tissues. Its Imaging Mass Cytometry (IMC) technology allows multiplexed imaging to understand the composition of tissue microenvironments at a subcellular 1-micron resolution. It markets technologies and life science tools, including preparatory and analytical instruments for mass cytometry, library prep, single cell genomics, and consumables, including integrated fluidic circuits (ifcs), assays, and reagents. Its analytical instruments include Biomark HD System, EP1 System, and Hyperion Tissue Imager.